Termed as Asia’s largest life sciences event, BioAsia 2024 showcased the convergence of pharma, biotech, healthcare and other allied companies adopting new cutting-edge technologies such as Artificial Intelligence (AI) and Big Data Analysis, catalysed fostering partnerships, collaborations, and new investments in the industries.
The three-day global bio event starting from February 26, was marked by the presence of more than 200 leading delegates from across 50 countries including, the USA, UK, France, Germany, Canada, Switzerland, and Australia, among others. The event also witnessed a footfall of over 10,500 participants from across various pharma, biotech, healthcare and other allied sectors.
Telangana Chief Minister Revanth Reddy, who inaugurated the BioAsia event made a significant announcement about the unveiling of the Genome
Valley Phase-II expansion on February 27, the second day of the event. The Genome Valley project which is proposed to come up over an extent of 300 acres is expected to attract Rs 2000 crore investment. The facility is set to span across Greenfield pharma clusters located in Vikarabad, Medak, and Nalgonda districts. Highlighting the project’s significance, CM Reddy accentuated its strategic placement near the Hyderabad International Airport, highlighting the convenience it provides for global entrepreneurs.
This ambitious venture apart from attracting thousands of crore rupees of investment is also expected to generate employment opportunities to 500,000 individuals in the state.
هذه القصة مأخوذة من طبعة BioSpectrum Asia April 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة BioSpectrum Asia April 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Australia develops AI sperm checker to enhance IVF success
Engineers in Australia have developed an artificial intelligence (AI) technology that accurately assesses the quality of live sperm in seconds, removing the need for invasive procedures that compromise sperm viability in vitro fertilisation (IVF) treatments.
Singapore discovers new fungus type, a possible global public health threat
Researchers from the Singapore General Hospital (SGH), A*STAR’s Genome Institute of Singapore (GIS) and Yong Loo Lin School of Medicine at National University of Singapore (NUS Medicine) have discovered a new clade (or type) of Candida auris, bringing the number of clades known globally to a total of six.
Singapore strengthens focus on computational biology
Singapore's National Quantum Office (NQO), Agency for Science, Technology and Research (A*STAR), National University of Singapore (NUS), National Supercomputing Centre (NSCC) and Quantinuum have signed a Memorandum of Understanding (MoU), enabling access to Quantinuum's advanced quantum computer, and to explore and collaborate on quantum computing use cases, focusing on computational biology.
Global scientists explore innovative tech to rapidly make new vaccine antigens
Researchers in the US are pursuing pioneering technology that may be able to rapidly create safe and effective vaccines against deadly epidemic and pandemic diseases that are more stable and less expensive than current vaccines.
Korea develops micro-structured artificial lung model using bioprinting technology
A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.
Philips names Ling Liu as Chief Region Leader of Greater China
Royal Philips, a global leader in health technology, has announced the appointment of Ling Liu as the Chief Region Leader of Philips Greater China.
PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals
PW Skills, the upskilling vertical of Physics Wallah (PW) has announced the launch of School of Healthcare across five cities in India, namely, Noida, Indore, Lucknow, Patna and Delhi.
Australian biotech incubator Proto Axiom announces $20 M Series B first close
Proto Axiom, the Australian biomedical technology incubator, has announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology sector through increased intellectual property (IP) retention.
Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology
Biogen Inc., Beckman Coulter, Inc. (both based in the US) and Japan-based Fujirebio have announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialise new tests for tau pathology in Alzheimer’s disease (AD).
Pfizer upgrades pharma production plant in Melbourne
Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria.
